Article
Empagliflozin reduces neointimal formation and vascular smooth muscle cell proliferation…
medRxiv · 2023 · Chen, W.-J.; Chang, G.-J.; Hsu, Y.-J.; Chen, Y.-H.
Key facts
| Title | Empagliflozin reduces neointimal formation and vascular smooth muscle cell proliferation via the suppression of PDGF-related signaling |
|---|---|
| First author | Chen, W.-J.; Chang, G.-J.; Hsu, Y.-J.; Chen, Y.-H. |
| Journal | medRxiv |
| Published | Aug 15, 2023 |
| DOI | 10.1101/2023.08.14.553316 |
| Product codes mentioned | KIP, KIT, NDS |
At a glance
- None FDA submissions mentioned
- 1–9 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1